CUE BIOPHARMA INC. - COMMON STOCK

Cue Biopharma Reports Second Quarter 2022 Financial Results

04 авг 2022 15:30:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

11 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the JMP Securities Life Sciences Conference

13 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the Jefferies Healthcare Conference

01 июн 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 май 2022 16:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

11 май 2022 07:01:12 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports First Quarter 2022 Financial Results

10 май 2022 15:30:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

10 мар 2022 07:00:02 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress

02 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

15 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

26 янв 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

20 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

05 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

15 дек 2021 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit

06 дек 2021 07:00:03 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

22 ноя 2021 07:00:02 Источник Nasdaq GlobeNewswire

Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

12 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

10 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases

21 окт 2021 11:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting

04 окт 2021 07:00:01 Источник Nasdaq GlobeNewswire